[go: up one dir, main page]

NO983474D0 - Expression of Group B Neisseria meningitidis outer membrane protein (MB3) from yeast and vaccines - Google Patents

Expression of Group B Neisseria meningitidis outer membrane protein (MB3) from yeast and vaccines

Info

Publication number
NO983474D0
NO983474D0 NO983474A NO983474A NO983474D0 NO 983474 D0 NO983474 D0 NO 983474D0 NO 983474 A NO983474 A NO 983474A NO 983474 A NO983474 A NO 983474A NO 983474 D0 NO983474 D0 NO 983474D0
Authority
NO
Norway
Prior art keywords
vaccines
yeast
expression
group
membrane protein
Prior art date
Application number
NO983474A
Other languages
Norwegian (no)
Other versions
NO983474L (en
Inventor
Joseph Y Tai
Michail Donets
Ming-Der Wang
Shu-Mei Liang
Marvellen Palvino-Bodnar
Conceicao A S A Minetti
Francis Michon
Original Assignee
North American Vaccine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North American Vaccine Inc filed Critical North American Vaccine Inc
Publication of NO983474D0 publication Critical patent/NO983474D0/en
Publication of NO983474L publication Critical patent/NO983474L/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NO983474A 1996-02-01 1998-07-28 Expression of Group B Neisseria meningitidis outer membrane (MB3) protein from yeast and vaccines NO983474L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1097296P 1996-02-01 1996-02-01
US2044096P 1996-06-13 1996-06-13
PCT/US1997/001687 WO1997028273A1 (en) 1996-02-01 1997-01-31 Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines

Publications (2)

Publication Number Publication Date
NO983474D0 true NO983474D0 (en) 1998-07-28
NO983474L NO983474L (en) 1998-09-30

Family

ID=26681820

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983474A NO983474L (en) 1996-02-01 1998-07-28 Expression of Group B Neisseria meningitidis outer membrane (MB3) protein from yeast and vaccines

Country Status (9)

Country Link
EP (1) EP0877816A1 (en)
JP (1) JP2001508758A (en)
KR (1) KR19990082265A (en)
AU (1) AU2115897A (en)
HU (1) HUP9901039A2 (en)
IL (1) IL125420A0 (en)
NO (1) NO983474L (en)
PL (1) PL328096A1 (en)
WO (1) WO1997028273A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451317B1 (en) 1997-07-17 2002-09-17 Baxter International Inc. Immunogenic conjugates comprising a Group B meningococcal porin and an H influenzae polysaccharide
CN101293920B (en) 1998-05-01 2012-07-18 诺华疫苗和诊断公司 Neisseria meningitidis antigens and compositions
DE69941406D1 (en) * 1998-07-06 2009-10-22 Tosoh Corp IL-6 receptor IL-6-coupled fusion protein
JP4524816B2 (en) * 1998-07-06 2010-08-18 東ソー株式会社 IL-6 receptor / IL-6 direct fusion protein
GB9818004D0 (en) * 1998-08-18 1998-10-14 Smithkline Beecham Biolog Novel compounds
JP2003518363A (en) 1999-04-30 2003-06-10 カイロン エセ.ピー.アー. Conserved Neisseria antigen
ID30407A (en) 1999-05-13 2001-11-29 American Cyanamid Co COMBINATION FORM FOR ADDITION MATERIALS
EP2270174A1 (en) * 1999-05-19 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
EP1069133A1 (en) * 1999-07-13 2001-01-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Neisseria meningitidis compounds and anti-infection applications thereof
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
JP4840956B2 (en) * 1999-11-29 2011-12-21 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 85kDa Neisseria antigen
ES2588917T3 (en) 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa VME supplement supplemented against meningococcus
CN100339482C (en) 2000-02-28 2007-09-26 启龙股份公司 Hybrid expression of neisserial proteins
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
SI2351579T1 (en) 2002-10-11 2017-05-31 Glaxosmithkline Biologicals Sa Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
CA2514328C (en) 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
JP2006262846A (en) * 2005-03-25 2006-10-05 Niigata Bio Research Park Kk Method for the synthesis and purification of 2-deoxy-siro-inosose by yeast and the resulting 2-deoxy-siro-inosose
KR100919704B1 (en) * 2007-09-12 2009-10-06 한국생명공학연구원 High-efficiency secretion of recombinant proteins in yeast
JP2011116658A (en) * 2008-03-13 2011-06-16 Chemo-Sero-Therapeutic Research Inst Manufacturing method of medicine for swine atrophic rhinitis
US9974848B2 (en) 2013-11-14 2018-05-22 Duke University Tetanus toxoid and CCL3 improve DC vaccines
CN106146679B (en) * 2015-04-23 2019-02-01 中国医学科学院医学生物学研究所 A kind of method of purification of bacterial capsular polysaccharide
ES2908463T3 (en) 2015-05-11 2022-04-29 Impossible Foods Inc Expression constructs and methods of genetic engineering of methylotrophic yeasts
US11441099B2 (en) * 2015-12-30 2022-09-13 Dsm Ip Assets B.V. Partial enzymatic hydrolysis of triacylglycerols
CA3137100A1 (en) * 2019-04-17 2020-10-22 Impossible Foods Inc. Materials and methods for protein production

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5268273A (en) * 1990-12-14 1993-12-07 Phillips Petroleum Company Pichia pastoris acid phosphatase gene, gene regions, signal sequence and expression vectors comprising same
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis

Also Published As

Publication number Publication date
JP2001508758A (en) 2001-07-03
HUP9901039A2 (en) 1999-07-28
AU2115897A (en) 1997-08-22
KR19990082265A (en) 1999-11-25
PL328096A1 (en) 1999-01-04
WO1997028273A1 (en) 1997-08-07
IL125420A0 (en) 1999-03-12
NO983474L (en) 1998-09-30
EP0877816A1 (en) 1998-11-18

Similar Documents

Publication Publication Date Title
NO983474D0 (en) Expression of Group B Neisseria meningitidis outer membrane protein (MB3) from yeast and vaccines
NO960256D0 (en) Expression, purification and refolding of Neisseria Meningitidis outer membrane group B protein proteins
IL99401A (en) Nucleotide sequence coding for an outer membrane protein from neisseria meningitidis and use of said protein in vaccine preparations
IS4879A (en) Preparations of dispersible macromolecules and methods for their preparation and use
NO993676L (en) Process for the preparation and purification of an N-alkylated aspartame derivative
DK1185666T3 (en) Hyaluronidase from Hirudinaria manillensis, isolation, purification and recombinant method of preparation
IS4345A (en) Substituted N- (indole-2-carbonyl) -b-alaninamide, their use and pharmaceutical preparations
DK0935441T3 (en) Method and apparatus for mapping cortical connections
NO972781D0 (en) Aerosol formulations of peptides and proteins
DE69623116D1 (en) GAS PERMEABLE MEMBRANE
CA2310888A1 (en) Monoclonal human natural antibodies
FI953025L (en) Impermeable and breathable membrane
NO972214L (en) Process for Purification and Isolation of 2'-Deoxy-2 ', 2'-Difluoronucleosides
NO971650L (en) Renibacterium salmoninarum vaccine and method of preparation thereof
DK0711501T3 (en) Method and apparatus for separating at least one piece of visceral tissue from at least one organ connected therein
NO974727D0 (en) Immunogenic and immunostimulatory oligosaccharide compositions and methods for their preparation
DK0845943T3 (en) New peptides derived from human heat shock protein 60 for the treatment of diabetes, compositions, methods and kits
NO982712D0 (en) Methods and intermediates for the preparation of 1-benzyl-4 - ((5,6-dimethoxy-1-indanone) -2-yl) methylpiperidine
DK0784986T3 (en) Artificial hair for implantation and method of preparation thereof
NO995034D0 (en) Dental implant system and method of manufacture thereof
NO951750L (en) Purified "nontypable" Haemophilus influenzae P5 protein as a vaccine for "nontypable" Haemophilus influenzae strain
DE69624128D1 (en) INHIBITANT AND NON-INHIBITING ANTI-BINDING POLYPEPTIDES AGAINST HUMAN P450 ENZYMS
NO911025D0 (en) PROCEDURE FOR INSULATION AND EXPRESSION OF HUMAN CILIAR NEURONOTROPIC FACTOR BY RECOMBINANT DNA TECHNOLOGY.
AU5735299A (en) Basb024 outer membrane protein of neisseria meningitidis
AU1087199A (en) Human vesicle membrane protein-like proteins